– Bloomberg
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.
Related Posts
Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
AI’s 2024 Reality Check: Facing ‘Peak AI Hype,’ It’s Time To Prove Its Worth
In 2024, AI will have to prove its worth, with investors seeking proof that billions spent on AI can make a return on investment. Microsoft, Palantir, and CrowdStrike are potential winners in 2024.
Here’s How Much $100 Invested In Inotiv 5 Years Ago Would Be Worth Today
Inotiv (NASDAQ:NOTV) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing…